Abpro Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABP research report →
Price Chart
About the company
Abpro Holdings, Inc. is a biotechnology firm dedicated to creating antibody-based treatments for patients suffering from conditions in immuno-oncology, ophthalmology, and autoimmunity. A key element of their strategy is the proprietary DiversImmune platform, which aims to resolve a significant hurdle in the antibody therapeutics sector.
- CEO
- Jin Wook Suk
- IPO
- 2022
- Employees
- 6
- HQ
- Woburn, MA, US
Get TickerSpark's AI analysis on ABP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.06M
- P/E
- 0.18
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.67
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -35.79%
- ROIC
- 189.87%
Latest fiscal year · YoY change
- Revenue
- $183.00K+50.0%
- Gross Profit
- $183.00K+50.0%
- Op Income
- $-9,921,000
- Net Income
- $-7,232,000+38.2%
- EPS
- $-23.10+38.4%
- OCF Growth
- -22.0%
- FCF Growth
- -21.2%
- 52W High
- $18.03
- 52W Low
- $0.11
- 50D MA
- $2.72
- 200D MA
- $5.62
- Beta
- -0.00
- RSI (14)
- 21
- Avg Volume
- 1.72M
No earnings-call transcripts are available for ABP yet.
- Free Float
- 54.1%
- Shares Outstanding
- 2.03M
- Float Shares
- 1.10M
Our ABP coverage
Recent articles, reports, and earnings notes.
No research on ABP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABP report →Short Interest in Abpro Holdings Inc. (NASDAQ:ABP) Increases By 271.4%
defenseworld.net · Feb 12
Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com · Jan 15
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
globenewswire.com · Jan 6
Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy?
defenseworld.net · Dec 19
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
globenewswire.com · Dec 15
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
globenewswire.com · Dec 9
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
globenewswire.com · Nov 4
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.